News | April 30, 2021
Indian vaccine players to garner Rs. 70,599 Cr in 2021
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
The Department of Pharmaceuticals launched the PLI scheme for promoting domestic manufacturing of bulk drugs, with a financial outlay of Rs. 6,940 crore across 53 APIs over 6 years
The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
Has signed a 12-year, off-site, virtual power purchase agreement (VPPA) with Enel Green Power
The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.
The pandemic has provided tailwinds in terms of access to rural healthcare and India’s emergence as a vaccine powerhouse
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
Biocon Ltd, an innovation-led global biopharmaceuticals company, has announced that the Board of its subsidiary Biocon Biologics Ltd has approved a primary equity investment of US $75 million (Rs. 555 crores) by Abu Dhabi based ADQ, one of the region’s largest holding companies.
Subscribe To Our Newsletter & Stay Updated
